Glycopyrronium bromide is a synthetic anticholinergic drug indicated for the treatment of gastrointestinal disorders like peptic ulcer, to diminish secretions and block cardiac vagal reflexes before surgery and for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Glycopyrronium, the quaternary ammonium ion of Glycopyrronium bromide occurs as a white, odorless powder and it exists both as crystalline or micronized powder.
Glycopyrronium is available on the market under different formulation, such tablets, lyophilized injections and capsules for Dry Powder Inhaler (DPI). Subministred to the lungs with DPI device, Glycopyrronium behaves as a long-acting muscarinic antagonist (LAMA) and it’s used for the maintenance treatment of patients with COPD.
Anticholinergic medicines such as Glycopyrronium bromide help the muscles around the airways in the lungs stay relaxed to prevent symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
Glycopyrronium is used for maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic lung disease that includes chronic bronchitis, emphysema, or both.
The drug is intended for long-term use and should be taken every day to improve symptoms of COPD for better breathing.
Glycopyrronium has been shown to provide rapid and sustained improvements in lung function, dyspnea, health status, exercise endurance and exacerbation risk and an acceptable safety and tolerability profile
At the same time, however, it is not used to treat sudden symptoms of COPD, where short-acting beta2-agonist medicine is recommended.
Products covered by valid patents in any country are not offered or supplied to these countries for commercial purpose.
Only the use for research and development is allowed.